INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Septerna, Inc. - SEPN

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Septerna, Inc and its officers or directors [1] Group 1: Company Overview - Septerna, Inc conducted its initial public offering (IPO) on October 25, 2024, offering 18.4 million shares at a price of $18.00 per share [2] - On February 18, 2025, Septerna announced the discontinuation of its Phase 1 clinical trial for SEP-786 due to two severe adverse events related to elevated unconjugated bilirubin [3] Group 2: Market Reaction - Following the announcement of the trial discontinuation, Septerna's stock price dropped by $6.09, representing a decline of 46.99%, closing at $6.87 per share on the same day [3]